Azenta (NASDAQ:AZTA – Get Free Report) and HeartSciences (NASDAQ:HSCS – Get Free Report) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, profitability, analyst recommendations, earnings, valuation and risk.
Volatility and Risk
Azenta has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500. Comparatively, HeartSciences has a beta of 2.53, suggesting that its stock price is 153% more volatile than the S&P 500.
Valuation and Earnings
This table compares Azenta and HeartSciences”s gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Azenta | $593.82 million | 1.54 | -$55.76 million | ($1.35) | -14.74 |
| HeartSciences | N/A | N/A | -$8.77 million | ($4.94) | -0.46 |
HeartSciences has lower revenue, but higher earnings than Azenta. Azenta is trading at a lower price-to-earnings ratio than HeartSciences, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Azenta and HeartSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Azenta | -10.34% | 1.43% | 1.19% |
| HeartSciences | N/A | -333.50% | -140.18% |
Analyst Ratings
This is a summary of recent ratings and price targets for Azenta and HeartSciences, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Azenta | 1 | 3 | 4 | 0 | 2.38 |
| HeartSciences | 1 | 0 | 1 | 0 | 2.00 |
Azenta presently has a consensus price target of $41.33, indicating a potential upside of 107.71%. HeartSciences has a consensus price target of $8.00, indicating a potential upside of 255.56%. Given HeartSciences’ higher probable upside, analysts clearly believe HeartSciences is more favorable than Azenta.
Institutional & Insider Ownership
99.1% of Azenta shares are owned by institutional investors. Comparatively, 17.2% of HeartSciences shares are owned by institutional investors. 10.9% of Azenta shares are owned by company insiders. Comparatively, 4.9% of HeartSciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Summary
Azenta beats HeartSciences on 8 of the 13 factors compared between the two stocks.
About Azenta
Azenta, Inc. provides biological and chemical compound sample exploration and management solutions for the life sciences market in North America, Africa, China, the United Kingdom, rest of Europe, the Asia Pacific, and internationally. The company operates in two reportable segments, Life Sciences Products and Life Sciences Services. The Life Sciences Products segment offers automated cold storage solutions, consumables and instruments, controlled rate thawing devices, and temperature-controlled storage and transportation solutions. This segment also provides sample management solutions, such as consumable vials and tubes, polymerase chain reaction, plates, instruments for supporting workflows, and informatics. The Life Sciences Services segment provides genomic services, that includes gene sequencing and gene synthesis services; and sample repository solutions, such as on-site and off-site sample storage, cold chain logistics, sample transport and collection relocation, bio-processing solutions, disaster recovery and business continuity, and biospecimen procurement services, as well as project management and consulting services for genomic analysis and the management and care of biological samples used in pharmaceutical, biotech, healthcare, clinical, and academic research, and development sectors. It serves a range of life science customers, including pharmaceutical companies, biotechnology companies, biorepositories, and research institutes. The company was formerly known as Brooks Automation, Inc. and changed its name to Azenta, Inc. in December 2021. Azenta, Inc. was founded in 1978 and is headquartered in Burlington, Massachusetts.
About HeartSciences
Heart Test Laboratories, Inc., a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals. The company was incorporated in 2007 and is headquartered in Southlake, Texas.
Receive News & Ratings for Azenta Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Azenta and related companies with MarketBeat.com's FREE daily email newsletter.
